Compare Harmony Gold Mining Co. (HMY) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Neurocrine Biosciences Inc — how do they compare? Harmony Gold Mining Co. trades at $16.88 (market cap $10.02B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Harmony Gold Mining Co. pays a 4.63% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harmony Gold Mining Co. for 45 Days and Neurocrine Biosciences Inc for 23 Days on average.
| HMY | NBIX | |
|---|---|---|
Market Cap | $10.02B | $14.36B |
Volume | 3,643,683 | 1,237,180 |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $185.50 |
52-Week Low | $13.32 | $123.10 |
Typical Hold Time | 45 Days | 23 Days |
Enterprise Value | $10.07B | $14.37B |
Dividend Yield | 4.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $16.84, up 2.12% today, showing strong profitability with 29.57% net margins and robust cash flow generation. The stock appears fundamentally undervalued with a P/E of 6.02 and EV/EBITDA of 3.54, though technical indicators signal bearish momentum with the price near key support levels. Recent earnings showed mixed results with two beats and two misses, while the company continues its strategic transition toward copper production diversification.
HMY presents a compelling value opportunity given its attractive valuation multiples and strong operational performance, but faces near-term technical headwinds and execution risks in its copper expansion strategy. The bearish technical setup and cautious analyst consensus (70% hold rating) suggest patience may be warranted despite the company's solid fundamentals and record fiscal 2026 results.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
